Safety and Tolerability of Research Lumbar Puncture in Huntington Disease: the HDClarity Cohort and Community Bioresource

被引：0
|
作者：
Rodrigues, Filipe B. [1 ]
Ehrhardt, Anka [2 ]
Owen, Gail [1 ]
Gosling, Stef [1 ]
Lifer, Sherry [2 ]
Neacy, Eileen [2 ]
Kaur, Dipinder [2 ]
Handley, Olivia [2 ,3 ]
Townhill, Jenny [2 ,3 ]
Leavitt, Blair [4 ]
Guttman, Mark [5 ]
Bang, Jee [6 ]
Levey, Jamie [2 ,6 ]
Pak, Elena [2 ]
Sampaio, Cristina [2 ]
Wild, Edward J. [1 ]
机构：
[1] UCL Queen Sq Inst Neurol, UCL Huntingtons Dis Ctr, London, England
[2] CHDI Fdn, CHDI Management, Princeton, NJ USA
[3] Univ Hosp Ulm, European Huntingtons Dis Network, Ulm, Germany
[4] Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC, Canada
[5] Univ Toronto, Div Neurol, Dept Med, Toronto, ON, Canada
[6] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
来源：
NEUROTHERAPEUTICS | 2018年 / 15卷 / 04期
基金：
英国医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
8
引用
收藏
页码：1171 / 1171
页数：1
相关论文
共 50 条
  • [41] The Safety and Efficacy of Stand-Alone Lateral Lumbar Interbody Fusion for Adjacent Segment Disease in a Cohort of 44 Patients
    Screven, Ryan
    Pressman, Elliot
    Rao, Gautam
    Freeman, Thomas B.
    Alikhani, Puya
    WORLD NEUROSURGERY, 2021, 149 : E225 - E230
  • [42] A safety, tolerability and biomarker update from an ongoing open-label extension study of RG6042 in adults with early manifest Huntington's disease
    Leavitt, B.
    Tabrizi, S.
    Ducray, P. Sanwald
    Wild, E.
    Schlegel, V.
    Hooper, G.
    Nicotra, A.
    Chevure, J.
    Smith, A.
    Lane, R.
    Bennett, F.
    Boak, L.
    Doody, R.
    Schobel, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [43] Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial
    Brownstein, Michael J.
    Simon, Neal G.
    Long, Jeffrey D.
    Yankey, Jon
    Maibach, Hilda T.
    Cudkowicz, Merit
    Coffey, Christopher
    Conwit, Robin A.
    Lungu, Codrin
    Anderson, Karen E.
    Hersch, Steven M.
    Ecklund, Dixie J.
    Damiano, Eve M.
    Itzkowitz, Debra E.
    Lu, Shifang
    Chase, Marianne K.
    Shefner, Jeremy M.
    McGarry, Andrew
    Thornell, Brenda
    Gladden, Catherine
    Costigan, Michele
    O'Suilleabhain, Padraig
    Marshall, Frederick J.
    Chesire, Amy M.
    Deritis, Paul
    Adams, Jamie L.
    Hedera, Peter
    Lowen, Kelly
    Rosas, H. Diana
    Hiller, Amie L.
    Quinn, Joseph
    Keith, Kellie
    Duker, Andrew P.
    Gruenwald, Christina
    Molloy, Angela
    Jacob, Cara
    Factor, Stewart
    Sperin, Elaine
    Bega, Danny
    Brown, Zsazsa R.
    Seeberger, Lauren C.
    Sung, Victor W.
    Benge, Melanie
    Kostyk, Sandra K.
    Daley, Allison M.
    Perlman, Susan
    Suski, Valerie
    Conlon, Patricia
    Barrett, Matthew J.
    Lowenhaupt, Stephanie
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 14
  • [44] A safety, tolerability and biomarker update from an ongoing open-label extension study of RG6042 in adults with early manifest Huntington's disease
    Tabrizi, S.
    Leavitt, B.
    Ducray, P. Sanwald
    Wild, E.
    Schlegel, V.
    Hooper, G.
    Nicotra, A.
    Chevure, J.
    Smith, A.
    Lane, R.
    Bennett, F.
    Boak, L.
    Doody, R.
    Schobel, S.
    MOVEMENT DISORDERS, 2019, 34 : S20 - S20
  • [45] Update on Open-label Extension of Pridopidine 45 mg Twice Daily in Huntington Disease (OPEN-HART): Safety, Tolerability, and Exploratory Efficacy.
    McGarry, A.
    Kieburtz, K.
    NEUROTHERAPEUTICS, 2016, 13 (01) : 250 - 251
  • [46] Safety of a novel modular cage for transforaminal lumbar interbody fusion - clinical cohort study in 20 patients with degenerative disc disease
    Elmekaty, Mohamed
    ElMehy, Emad
    Forsth, Peter
    MacDowall, Anna
    El Elemi, Ahmed
    Hosni, Mohamed
    Robinson, Yohan
    SICOT-J, 2018, 4
  • [47] A PHASE 2 OPEN LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS ANX005 IN PATIENTS WITH, OR AT RISK OF, MANIFEST HUNTINGTON'S DISEASE (HD)
    Kumar, Rajeev
    Claassen, Daniel O.
    Mongan, Ann
    Hoehn, Benjamin
    Lin, Ping
    Cahir-Mcfarland, Ellen
    Taylor, Lori
    Chandra, Priya
    Yednock, Ted
    Kroon, Henk-Andre
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 : A96 - A97
  • [48] Dextromethorphan/Quinidine: Safety, Tolerability, and Effectiveness for Pseudobulbar Affect in Patients with Alzheimer's Disease/Dementia: PRISM-II-Dementia-Cohort Results
    Doody, R. S.
    D'Amico, S.
    Cutler, A. J.
    Shin, P.
    Ledon, E.
    Yonan, C.
    Siffert, J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2015, 63 : S34 - S34
  • [49] Full dose, daily sofosbuvir treatment in end-stage renal disease: tolerability & safety of largest ESRD patient cohort exposed to this drug
    Nazario, H. E.
    Modi, A. A.
    Ndungu, M.
    Ramirez, R.
    Tujague, L.
    Weinstein, J. S.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S506 - S507
  • [50] A Phase 2 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX005 in Patients with, or at Risk of, Manifest Huntington's Disease (HD)
    Kumar, Rajeev
    Claassen, Daniel
    Mongan, Ann
    Hoehn, Benjamin
    Lin, Ping
    Cahir-Mcfarland, Ellen
    Guo, Chenying
    Volman, Vladislav
    Taylor, Lori
    Chandra, Priya
    Yednock, Ted
    Kroon, Henk-Andre
    NEUROLOGY, 2023, 100 (17)
12345